Screener
Axsome Therapeutics AXSM Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Short-term borrowings | 70,000 | 70,000 |
| Total current liabilities | 439,211 | 378,836 |
| Contingent consideration, non-current | 73,730 | 77,540 |
| Loan payable, long-term | 117,850 | 117,746 |
| Operating lease liability, long-term | 22,385 | 23,182 |
| Finance lease liability, long-term | 5,844 | 4,206 |
| Total liabilities | 659,020 | 601,510 |
| Stockholders’ equity: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's long-term debt?
- Axsome Therapeutics (AXSM) reported long-term debt of $117.85M in Q1 2026.
- How has Axsome Therapeutics's long-term debt changed year-over-year?
- Axsome Therapeutics's long-term debt decreased by 35.0% year-over-year, from $181.38M to $117.85M.
- What is the long-term trend for Axsome Therapeutics's long-term debt?
- Over 5 years (2020 to 2025), Axsome Therapeutics's long-term debt has grown at a 19.5% compound annual growth rate (CAGR), from $48.32M to $117.75M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Axsome Therapeutics's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude